Botanix attends USA healthcare conferences

Latest News

Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it is attending and key investor conferences in the US in January - the JP Morgan Healthcare and Dermatology Summit conferences.

The company said it will use the conferences to meet with a number of industry and investor parties to provide an update on the recent Phase 2 acne clinical study and the current clinical programs.

It said the BTX 1204 atopic dermatitis clinical study is nearing completion and remains on target for data readout this quarter, while the BTX 1702 rosacea Phase 1b study plans to commence enrolling patients this quarter.

According to Vince Ippolito, President and Executive Chairman, “We are very pleased to be kicking off the year with the Dermatology Summit and JP Morgan Healthcare conferences.

“These events provide an invaluable opportunity to engage with potential partners, as well as current and future investors to relate our successes and plans for 2020 and beyond.”